Evidence map›Paper›PMID 40108438›Full record

ArticleEuropean journal of human genetics : EJHG2025

Heterozygous CELF4 variants in the N-term region crucial for the RNA-binding activity lead to neurodevelopmental disorder and obesity.

Ange-Line Bruel, Anneke T Vulto-vanSilfhout, Frédéric Bilan, Gwenaël Le Guyader, Brigitte Gilbert-Dussardier, Xavier Le Guillou, Sophie Rondeau, Marlène Rio, Kristen N Lee, Adelyn Beil and 26 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Summer reading 2025 in EJHG.European journal of human genetics : EJHG · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Ange-Line BruelINSERM UMR 1231, Génétique des Anomalies du Développement, Université de Bourgogne Franche-Comté, Dijon, France. ange-line.bruel@u-bourgogne.fr.ORCID 0000-0002-0526-465X
Anneke T Vulto-vanSilfhoutDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Frédéric BilanDepartment of Genetics, CHU de Poitiers, Poitiers, France.
Gwenaël Le GuyaderDepartment of Genetics, CHU de Poitiers, Poitiers, France.ORCID 0000-0003-2847-8121
Brigitte Gilbert-DussardierDepartment of Genetics, CHU de Poitiers, Poitiers, France.ORCID 0000-0001-7182-9914
Xavier Le GuillouDepartment of Genetics, CHU de Poitiers, Poitiers, France.ORCID 0000-0001-9350-8177
Sophie RondeauDepartment of Genetics, Necker Enfants Malades Hospital, Paris Descartes-Sorbonne Paris Cité University, Paris, France.
Marlène RioDepartment of Genetics, Necker Enfants Malades Hospital, Paris Descartes-Sorbonne Paris Cité University, Paris, France.ORCID 0000-0003-2049-5058
Kristen N LeeDepartment of Pediatrics, Division of Pediatric Genetics, Metabolism and Genomic Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-7326-9973
Adelyn BeilDepartment of Pediatrics, Division of Pediatric Genetics, Metabolism and Genomic Medicine, University of Michigan, Ann Arbor, MI, USA.
Mohnish SuriNottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, UK.
François GuerinService de Pédiatrie, CH de La Rochelle, La Rochelle, France.
Valentin RuaultMedical Genetics and Rare Diseases Department, Montpellier University Hospital, Montpellier, France.
Alice GoldenbergDepartment of Genetics and Reference Center for Developmental Disorders, Rouen Normandie University, Inserm U12045 and CHU Rouen, FHU-G4 Génomique, Rouen, France.
François LecoquierreDepartment of Genetics and Reference Center for Developmental Disorders, Rouen Normandie University, Inserm U12045 and CHU Rouen, FHU-G4 Génomique, Rouen, France.ORCID 0000-0002-9110-1856
Nicole BertschThe Community Health Clinic Shipshewana, Shipshewana, IN, USA.
Rhonda AndersonThe Community Health Clinic Shipshewana, Shipshewana, IN, USA.
Xiao-Ru YangDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Micheil InnessDepartment of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Emi Rikeros-OrozcoInstituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain.
Maria Palomares-BraloInstituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain.
Jennifer Cassady HayekSeattle Children's Hospital, Seattle, WA, USA.ORCID 0009-0003-5785-9406
Jennifer CechSeattle Children's Hospital, Seattle, WA, USA.
Ankita JhuraneyUniversity of Washington Medical Center, Seattle, WA, USA.
Runjun D KumarUniversity of Washington Medical Center, Seattle, WA, USA.
Saadet Mercimek-AndrewsDepartment of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Anastasia AmbroseDepartment of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Erin N WakelingGeneDx, Gaitherburg, MD, USA.
Ingrid M WentzensenGeneDx, Gaitherburg, MD, USA.
Erin TortiGeneDx, Gaitherburg, MD, USA.
Catherine GoochDepartment of Pediatrics, Division of Genetics and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Laurence FaivreINSERM UMR 1231, Génétique des Anomalies du Développement, Université de Bourgogne Franche-Comté, Dijon, France.ORCID 0000-0001-9770-444X
Christophe PhilippeINSERM UMR 1231, Génétique des Anomalies du Développement, Université de Bourgogne Franche-Comté, Dijon, France.ORCID 0000-0001-7098-6520
Yannis DuffourdINSERM UMR 1231, Génétique des Anomalies du Développement, Université de Bourgogne Franche-Comté, Dijon, France.
Antonio VitobelloINSERM UMR 1231, Génétique des Anomalies du Développement, Université de Bourgogne Franche-Comté, Dijon, France.ORCID 0000-0003-3717-8374
Christel Thauvin-RobinetINSERM UMR 1231, Génétique des Anomalies du Développement, Université de Bourgogne Franche-Comté, Dijon, France.ORCID 0000-0002-4155-139X

Funding

Physicians' Services Incorporated Foundation (PSI Foundation) Mercimek-Andrews SaadetPhysicians' Services Incorporated Foundation (PSI Foundation) Saadet Mercimek-Andrews
6 · The paper itself

Abstract

RNA-binding proteins play a key role in post-transcriptional events, such as mRNA splicing, transport, stability, translation and decay. Dysregulation of RNA life can have dramatic consequences. CELF RNA-binding proteins appear to be essential during embryo development. In this study, we identified 15 patients with heterozygous missense or loss-of-function variants in the CELF4 gene by exome or genome sequencing. All variants affecting the N-terminus of the protein are essential and sufficient for the RNA-binding and splicing activity or RRM domains. Most patients presented with neurodevelopmental disorders including global developmental delay/intellectual disability (11/14), seizures (9/15) and overweight/obesity (10/14) that began in childhood. Clinical features are similar to the reported celf4-mouse mutant phenotype. This study highlights the essential role of CELF4 in development and its involvement as a novel etiology of neurodevelopmental disorders with obesity.

Indexed as

CELF ProteinsNeurodevelopmental DisordersObesityAdolescentChildChild, PreschoolFemaleHeterozygoteHumansInfantIntellectual DisabilityLoss of Function MutationMaleMutation, MissenseCELF Proteins

Identifiers

PMID40108438
PMCPMC12229443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.